GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reported a buyback of 170,000 ordinary shares on 10 November 2025 under its existing programme via BNP Paribas SA. Prices ranged from 1,753.50p to 1,779.00p per share, with a volume‑weighted average price of 1,768.72p.
Since 30 September 2025, GSK has purchased 8,329,000 ordinary shares. After this purchase, GSK holds 255,793,844 shares in treasury and has 4,059,634,530 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,059,634,530, and the percentage of voting rights attributable to treasury shares is 6.30%. Trades were executed on the London Stock Exchange and Cboe Europe order books.
GSK published provisional 2026 dividend timetable; dates are indicative and may change.
Q1: announce April 29, ex-div May 14 (ADS May 15), record May 15, DRIP June 18, payable July 9. Q2: announce July 29, ex-div August 13 (ADS August 14), record August 14, DRIP September 17, payable October 8. Q3: announce October 28, ex-div November 12 (ADS November 13), record November 13, DRIP December 14, payable January 7, 2027. Q4: announce February 3, 2027, ex-div February 18 (ADS February 19), record February 19, DRIP March 16, payable April 8, 2027.
GSK repurchased 170,000 ordinary shares on 07 November 2025 at a volume‑weighted average price of 1,772.64p (low 1,757.50p; high 1,788.50p) under its existing buyback programme via BNP Paribas SA. The shares will be held as treasury shares.
Since 30 September 2025, GSK has bought 8,159,000 shares. Following this transaction, it holds 255,623,844 shares in treasury and has 4,059,804,530 shares in issue (excluding treasury). Total voting rights are 4,059,804,530, and treasury shares represent 6.30% of voting rights.
GSK plc reported a buyback transaction executed through BNP Paribas SA, purchasing 170,000 ordinary shares on 06 November 2025 at a volume‑weighted average price of 1,778.72p (range: 1,769.50p–1,786.00p). The shares will be held as treasury shares and the trade forms part of the existing buyback programme under a non‑discretionary agreement announced on 30 September 2025. Since that date, GSK has purchased 7,989,000 shares.
After this purchase, GSK holds 255,453,844 shares in treasury and has 4,059,969,755 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,059,969,755, and the percentage of voting rights attributable to treasury shares is 6.29%.
GSK plc repurchased 170,000 ordinary shares on 05 November 2025 as part of its existing buyback programme, executed via BNP Paribas SA. Prices ranged from 1,779.00p to 1,798.00p with a volume‑weighted average price of 1,789.04p. The purchased shares will be held as treasury shares.
Since 30 September 2025, the company has purchased 7,819,000 ordinary shares. After this transaction, GSK holds 255,283,844 shares in treasury and has 4,060,139,755 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,060,139,755, and the percentage of voting rights attributable to treasury shares is 6.29 per cent.
GSK plc reported a routine share buyback under its existing programme. On 04 November 2025, the company repurchased 175,000 ordinary shares at prices between 1,747.00p and 1,790.00p, with a volume‑weighted average price of 1,768.39p. The shares will be held as Treasury shares.
The purchase was executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025. Since 30 September 2025, 7,649,000 shares have been bought. After this transaction, GSK holds 255,113,844 shares in treasury and has 4,060,309,755 shares in issue (excluding treasury). The total number of voting rights is 4,060,309,755, and the percentage of voting rights attributable to treasury shares is 6.28%.
GSK plc reported a routine share buyback under its non‑discretionary agreement with BNP Paribas SA. On 03 November 2025, the company purchased 170,500 ordinary shares of 31¼ pence each at a lowest price 1,758.50p, highest price 1,782.00p, and volume‑weighted average price (VWAP) 1,769.85p. The shares will be held as Treasury shares and form part of the existing buyback programme announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 7,474,000 ordinary shares. After the latest transaction, GSK holds 254,938,844 shares in treasury and has 4,060,484,755 ordinary shares in issue (excluding treasury). The total voting rights are 4,060,484,755, and the percentage of voting rights attributable to treasury shares is 6.28%.
GSK plc reported its monthly total voting rights and capital. As at 31 October 2025, the company had 4,315,423,599 Ordinary Shares of 31 ¼ pence each in issue, of which 254,768,344 were held in treasury. The resulting total number of voting rights is 4,060,655,255.
Shareholders may use this voting rights figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
GSK plc reported a share buyback transaction executed via BNP Paribas SA, purchasing 175,000 ordinary shares on 31 October 2025. Prices ranged from 1,760.00p to 1,791.50p with a volume‑weighted average price of 1,780.09p. The shares will be held as Treasury shares as part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025. Since 30 September 2025, the Company has purchased 7,303,500 shares.
After this purchase, GSK holds 254,768,344 shares in treasury and has 4,060,655,255 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,060,655,255, and treasury shares represent 6.27% of voting rights. The filing also provides a venue‑level breakdown and individual trade details for trades on XLON, CHIX and BATE.
GSK plc reported a daily share repurchase under its existing buyback programme. On 30 October 2025, the company bought 180,000 ordinary shares at prices between 1,726.50p and 1,780.00p, with a volume-weighted average price of 1,756.23p. The shares will be held as treasury shares.
Since 30 September 2025, GSK has purchased 7,128,500 ordinary shares. Following this transaction, GSK holds 254,593,344 ordinary shares in treasury and has 4,060,827,442 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,060,827,442, and the percentage of voting rights attributable to treasury shares is 6.27%.